Navigation Links
Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
Date:3/25/2008

HOPKINTON, Mass., March 25 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will host a conference call on Tuesday, April 1st, 2008 at 10:00am EDT to review 2007 Financial Results and discuss other matters related to the Company.

To access the conference call, please dial 877-718-5104 for domestic and 719-325-4843 international. The code for this conference call is 7767549. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of the website, http://www.alseres.com, within 48 hours following the conference call and will be available through Tuesday, April 15th, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including b
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
2. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
3. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
4. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
5. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
6. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
7. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
9. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
10. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
11. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...- Biomedical engineers at The University of Texas ...ave announced pre-clinical test results in the Sep...edicine demonstrating the feasibility of a smart p... in glucose or blood sugar levels and releases ins...tions of the pancreas which produces the blood-sug...
...nc. (Nasdaq:,SQNM) today announced that a live aud...l be provided for its analyst and investor briefin...the event are as follows: (Logo: http://www.new... Sequenom Today and Tomorrow, When: Monday...here: http://www.sequenom.com , How: Liv...
...l Alliance, the leading,management consulting firm...dustries, today announced that Ben Bonifant, Vice ...ent practice, will moderate a panel discussion,at ...rence hosted by,Windhover Information. The confere...iott Financial Center in New York City. The panel...
Other Biology Technology:Smart insulin nanostructures pass feasibility test, UT study reports 2Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 3
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 1Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 210 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 110 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 2Human Pheromones 3A Whats Purported Whats Supported A White Paper Published by The Sense of Smell Institute 53249 1
... for Medical Research (Burnham) have discovered a ... Sporadic Inclusion Body Myositis (sIBM). sIBM is ...men, causing muscles to gradually weaken and waste...known, but it is the most common muscle disease am...iliarity, it is probably underdiagnosed. This disc...
...cal Research Institute report that bats significan...In a lowland tropical rainforest in Panama, bats c...cts as do birds. This landmark study in the journa...ats and birds to protect plants via insect predati...dy by the authors suggested that bats were underes...
... University have pinpointed a small group of genes...w to produce a hormone that is key to their develo...ich hormone production in plants affects both a pl...nvironments. , Dr. Jose Alonso, assistant profes...nt biologists from NC State, Germany and the Czech...
Other Biology News:RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2NC State researchers identify genes key to hormone production in plants 2
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
...bbit polyclonal to Kv4.2 Immunogen Synthetic pep...rresponding to amino acids 23-43 of Rat Kv4.2. Re...cted to cross-react with Human (100% identity with... Rabbit (100% identity with immunogen) and Ferret ...
Biology Products: